异动解读 | AI药物研发龙头晶泰控股盘中大涨8.09%，南向资金连续7日增持

异动解读

Sep 05, 2025

周五盘中，港股生物医药板块AI药物研发龙头晶泰控股（02228）股价大涨8.09%，引起市场广泛关注。这一强劲表现背后，有多重利好因素支撑。

首先，晶泰控股上半年业绩亮眼。公司深耕AI药物发现领域，今年上半年药物发现解决方案业务收入达4.35亿元，同比大增615.2%。这一亮眼表现带动公司整体营收同比增长403.8%至5.17亿元，显示出公司在AI赋能药物研发方面的强劲实力和市场认可度。

其次，南向资金持续看好晶泰控股。据报道，9月4日南向资金增持晶泰控股2806.30万股，这已经是连续第7个交易日增持。截至9月4日收盘，港股通共持有晶泰控股175088.99万股，占流通股43.59%。这种持续的资金流入反映了机构投资者对公司发展前景的信心。此外，在9月4日港股通（沪）十大成交榜中，晶泰控股位列第十，成交额达12.51亿元，净流入0.61亿元，进一步证实了资金对该股的青睐。

综上所述，晶泰控股作为AI药物研发领域的领先企业，凭借其出色的业绩表现和持续获得的资金支持，吸引了市场的高度关注。随着生物医药行业创新步伐加快，AI技术在药物研发中的应用日益广泛，晶泰控股有望继续受益于行业发展趋势，保持增长势头。投资者应密切关注公司后续发展动态及行业政策变化。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1199659528"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199659528\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199659528?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-05 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199659528","market":"nz","top_or_hot":-1,"title":"异动解读 | AI药物研发龙头晶泰控股盘中大涨8.09%，南向资金连续7日增持","media":"异动解读","content":"<p>周五盘中，港股生物医药板块AI药物研发龙头晶泰控股（02228）股价大涨8.09%，引起市场广泛关注。这一强劲表现背后，有多重利好因素支撑。</p>\n\n<p>首先，晶泰控股上半年业绩亮眼。公司深耕AI药物发现领域，今年上半年药物发现解决方案业务收入达4.35亿元，同比大增615.2%。这一亮眼表现带动公司整体营收同比增长403.8%至5.17亿元，显示出公司在AI赋能药物研发方面的强劲实力和市场认可度。</p>\n\n<p>其次，南向资金持续看好晶泰控股。据报道，9月4日南向资金增持晶泰控股2806.30万股，这已经是连续第7个交易日增持。截至9月4日收盘，港股通共持有晶泰控股175088.99万股，占流通股43.59%。这种持续的资金流入反映了机构投资者对公司发展前景的信心。此外，在9月4日港股通（沪）十大成交榜中，晶泰控股位列第十，成交额达12.51亿元，净流入0.61亿元，进一步证实了资金对该股的青睐。</p>\n\n<p>综上所述，晶泰控股作为AI药物研发领域的领先企业，凭借其出色的业绩表现和持续获得的资金支持，吸引了市场的高度关注。随着生物医药行业创新步伐加快，AI技术在药物研发中的应用日益广泛，晶泰控股有望继续受益于行业发展趋势，保持增长势头。投资者应密切关注公司后续发展动态及行业政策变化。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | AI药物研发龙头晶泰控股盘中大涨8.09%，南向资金连续7日增持</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | AI药物研发龙头晶泰控股盘中大涨8.09%，南向资金连续7日增持\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-09-05 11:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>周五盘中，港股生物医药板块AI药物研发龙头晶泰控股（02228）股价大涨8.09%，引起市场广泛关注。这一强劲表现背后，有多重利好因素支撑。</p>\n\n<p>首先，晶泰控股上半年业绩亮眼。公司深耕AI药物发现领域，今年上半年药物发现解决方案业务收入达4.35亿元，同比大增615.2%。这一亮眼表现带动公司整体营收同比增长403.8%至5.17亿元，显示出公司在AI赋能药物研发方面的强劲实力和市场认可度。</p>\n\n<p>其次，南向资金持续看好晶泰控股。据报道，9月4日南向资金增持晶泰控股2806.30万股，这已经是连续第7个交易日增持。截至9月4日收盘，港股通共持有晶泰控股175088.99万股，占流通股43.59%。这种持续的资金流入反映了机构投资者对公司发展前景的信心。此外，在9月4日港股通（沪）十大成交榜中，晶泰控股位列第十，成交额达12.51亿元，净流入0.61亿元，进一步证实了资金对该股的青睐。</p>\n\n<p>综上所述，晶泰控股作为AI药物研发领域的领先企业，凭借其出色的业绩表现和持续获得的资金支持，吸引了市场的高度关注。随着生物医药行业创新步伐加快，AI技术在药物研发中的应用日益广泛，晶泰控股有望继续受益于行业发展趋势，保持增长势头。投资者应密切关注公司后续发展动态及行业政策变化。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02228","symbol_name":"晶泰控股","start_time":0,"source_url":"","article_id":"1199659528","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199659528","pubTimestamp":1757042568,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"周五盘中，港股生物医药板块AI药物研发龙头晶泰控股股价大涨8.09%，引起市场广泛关注。首先，晶泰控股上半年业绩亮眼。据报道，9月4日南向资金增持晶泰控股2806.30万股，这已经是连续第7个交易日增持。截至9月4日收盘，港股通共持有晶泰控股175088.99万股，占流通股43.59%。随着生物医药行业创新步伐加快，AI技术在药物研发中的应用日益广泛，晶泰控股有望继续受益于行业发展趋势，保持增长势头。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02228":"晶泰控股"},"translate_title":"Interpretation of changes | Jingtai Holdings, the leader in AI drug research and development, rose 8.09% during the session, and southbound funds increased their holdings for 7 consecutive days","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1},"content_text":"周五盘中，港股生物医药板块AI药物研发龙头晶泰控股（02228）股价大涨8.09%，引起市场广泛关注。这一强劲表现背后，有多重利好因素支撑。\n首先，晶泰控股上半年业绩亮眼。公司深耕AI药物发现领域，今年上半年药物发现解决方案业务收入达4.35亿元，同比大增615.2%。这一亮眼表现带动公司整体营收同比增长403.8%至5.17亿元，显示出公司在AI赋能药物研发方面的强劲实力和市场认可度。\n其次，南向资金持续看好晶泰控股。据报道，9月4日南向资金增持晶泰控股2806.30万股，这已经是连续第7个交易日增持。截至9月4日收盘，港股通共持有晶泰控股175088.99万股，占流通股43.59%。这种持续的资金流入反映了机构投资者对公司发展前景的信心。此外，在9月4日港股通（沪）十大成交榜中，晶泰控股位列第十，成交额达12.51亿元，净流入0.61亿元，进一步证实了资金对该股的青睐。\n综上所述，晶泰控股作为AI药物研发领域的领先企业，凭借其出色的业绩表现和持续获得的资金支持，吸引了市场的高度关注。随着生物医药行业创新步伐加快，AI技术在药物研发中的应用日益广泛，晶泰控股有望继续受益于行业发展趋势，保持增长势头。投资者应密切关注公司后续发展动态及行业政策变化。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}